Jens U Wuerthner
Overview
Explore the profile of Jens U Wuerthner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
282
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bauer S, Demetri G, Halilovic E, Dummer R, Meille C, Tan D, et al.
Br J Cancer
. 2021 Jun;
125(5):687-698.
PMID: 34140638
Background: CGM097 inhibits the p53-HDM2 interaction leading to downstream p53 activation. Preclinical in vivo studies support clinical exploration while providing preliminary evidence for dosing regimens. This first-in-human phase I study...
2.
Wang H, Halilovic E, Li X, Liang J, Cao Y, Rakiec D, et al.
Elife
. 2017 Apr;
6.
PMID: 28425916
The efficacy of ALK inhibitors in patients with -mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end, we sought to develop a...
3.
Reuther C, Heinzle V, Nolting S, Herterich S, Hahner S, Halilovic E, et al.
Neuroendocrinology
. 2016 Nov;
106(1):1-19.
PMID: 27871087
Background/aims: The tumor suppressor p53 is depleted in many tumor cells by the E3 ubiquitin ligase mouse double minute 2 homolog (MDM2) through MDM2/p53 interaction. A novel target for inhibiting...
4.
Townsend E, Murakami M, Christodoulou A, Christie A, Koster J, DeSouza T, et al.
Cancer Cell
. 2016 Aug;
30(1):183.
PMID: 27479034
No abstract available.
5.
Townsend E, Murakami M, Christodoulou A, Christie A, Koster J, DeSouza T, et al.
Cancer Cell
. 2016 Apr;
29(4):574-586.
PMID: 27070704
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could...
6.
Weisberg E, Halilovic E, Cooke V, Nonami A, Ren T, Sanda T, et al.
Mol Cancer Ther
. 2015 Jul;
14(10):2249-59.
PMID: 26206331
The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2 family proteins. In cells expressing wild-type...